Market Place
Sourcing Support
All News #Library
Rare Diseases
Rezolute Shares CHI Hyperinsulinism Update Post-FDA Meeting
24 Mar 2026 //
GLOBENEWSWIRE
Rezolute Shares sunRIZE Phase 3, EAP Program Insights at CHI
07 Jan 2026 //
GLOBENEWSWIRE
Rezolute Stock Sinks 87% As Hypoglycemia Drug Fails Ph. 3 Test
12 Dec 2025 //
FIERCE BIOTECH
Rezolute Plans Virtual Investor Event For Ersodetug Development
05 Nov 2025 //
GLOBENEWSWIRE
Rezolute Issues Inducement Grant Per Nasdaq LR 5635(C)(4)
09 Oct 2025 //
GLOBENEWSWIRE
Rezolute Aligns with FDA for Phase 3 Trial of Ersodetug in Tumor
02 Sep 2025 //
GLOBENEWSWIRE
Rezolute Recruits Ex-Ultragenyx Exec for Rare Disease Launch
21 Aug 2025 //
FIERCE PHARMA
Rezolute Names Sunil Karnawat as Chief Commercial Officer
20 Aug 2025 //
GLOBENEWSWIRE
Rezolute to Share Phase 3 Data on Ersodetug for Hyperinsulinism
09 Jul 2025 //
GLOBENEWSWIRE
Rezolute Completes Enrollment in Phase 3 Study of Ersodetug
28 May 2025 //
GLOBENEWSWIRE
Rezolute Reports Q3 Fiscal 2025 Results and Business Update
13 May 2025 //
GLOBENEWSWIRE
Rezolute to Participate in Upcoming Investor Conferences
01 May 2025 //
GLOBENEWSWIRE
Rezolute Appoints Rare Disease Leader Erik Harris to Board
26 Mar 2025 //
GLOBENEWSWIRE
Rezolute Reports Q2 Fiscal 2025 Financial Results & Update
12 Feb 2025 //
GLOBENEWSWIRE
FDA Grants Orphan Drug Designation to Rezolute for Hypoglycemia
03 Dec 2024 //
GLOBENEWSWIRE
FDA Lifts Partial Clinical Holds On RZ358
09 Sep 2024 //
GLOBENEWSWIRE
Rezolute`s IND For RZ358 Phase 3 Study Cleared By FDA
05 Aug 2024 //
GLOBENEWSWIRE
Copyright © 2026 LePro PharmaCompass OPC Private Limited, All rights reserved.